Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “mesonephric adenocarcinoma”.

Human onlyPositive outcomesSafety signalsTrials4 of 200 studies

ReviewMechanismInconclusiveLimited evidenceTier 3 · early human

Mesonephric-like Adenocarcinoma of the Female Genital Tract: A Comprehensive Review of Clinicopathological, Immunophenotypic, Molecular Features, and Clinical Management

International journal of surgical pathology · Jun 2026 · comprehensive review

mesonephric-like adenocarcinoma (MLA)mesonephric adenocarcinoma (MA)female genital tractuterine cervix

This is a comprehensive review summarizing clinicopathologic, immunophenotypic, and molecular features of mesonephric-like adenocarcinoma (MLA) of the female genital tract. The authors report that MLA shows diverse histologic patterns, is typically negative or only focally positive for ER, is positive for TTF-1, CD10, and GATA3 immunostains, and often harbors KRAS mutations. They note that MLA resembles mesonephric adenocarcinoma histologically and molecularly but, unlike MA, is not associated with mesonephric remnants. The review aims to improve clinicians' and pathologists' recognition of this rare tumor type.

Key findings

MLA is a recently recognized rare malignancy of the female genital tract with histomorphology, immunohistochemistry, and molecular characteristics similar to mesonephric adenocarcinoma but not associated with mesonephric remnants.
Histologic patterns described for MLA include tubule-like, glandular, papillary, solid, sex cord-like, trabecular, retiform, cribriform, glomeruloid, and spindle cell patterns.
Immunohistochemically, most MLAs show negative or focal weak expression for ER and are positive for TTF-1, CD10, and GATA3.
Molecularly, these tumors often harbor KRAS gene mutations.

Limitations: This is a narrative review rather than primary original data.; No systematic review or meta-analytic methods are described in the abstract.; MLA is a rare tumor, so primary evidence summarized may be limited in quantity and quality.; The abstract does not report treatment or clinical outcome data..

Provides a clinicopathologic, immunophenotypic, and molecular summary intended to help pathologists and clinicians recognize and diagnose mesonephric-like adenocarcinoma.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 21

HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · May 2026

Trastuzumab-deruxtecan-t-dxdmesonephric adenocarcinoma (cervix)mesonephric-like adenocarcinoma (endometrium)mesonephric-like adenocarcinoma (ovary)

The authors measured HER2 and FOLR1 protein expression by immunohistochemistry in 21 mesonephric and mesonephric-like gynecologic adenocarcinomas (13 endometrial, 5 ovarian, 3 cervical). HER2 was detectable in 14 of 21 tumors (two cases scored 2+ and many scored 1+, with no 3+ cases), while FOLR1 met MIRV eligibility in one case and ten additional tumors had 5–70% expression. Most tumors did not meet current thresholds for HER2- or FOLR1-targeted monotherapy, but the authors suggest detectable expression could justify exploring T-Dxd and MIRV combinations in selected cases.

Reported effects: Total cases assessed 21 · endometrial cases 13, n=21 · +9 more

Studied with: trastuzumab deruxtecan + mirvetuximab soravtansine.

Key findings

HER2 expression was present in 14/21 tumors.
HER2 (2+) was seen in two cases by both EC and GaC criteria; no HER2 (3+) was identified.
Twelve other cases showed HER2 (1+) by endometrial cancer (EC) criteria; only four met 1+ by GaC criteria.
FOLR1 met current MIRV treatment criteria in one case; ten other cases showed FOLR1 expression ranging from 5% to 70%.
Most tumors did not meet current biomarker thresholds for trastuzumab (HER2) or MIRV monotherapy.

Limitations: Small sample size (21 cases).; Observational immunohistochemical study of archival tumors only — no treatment or clinical outcome data provided.; Heterogeneous primary sites (cervix, endometrium, ovary) which may affect biomarker distribution.; Use of different scoring criteria (EC vs GaC) produced discordant HER2 categorization, which may limit generalizability..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 13

Mesonephric and Mesonephric-like Adenocarcinomas of the Gynecologic Tract: A Case Series and a Review of the Literature

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · Nov 2025 · retrospective case series (chart review)

mesonephric adenocarcinomamesonephric-like adenocarcinomauterine adenocarcinomaovarian adenocarcinomacervical adenocarcinoma

This retrospective case series describes 13 patients with mesonephric and mesonephric-like adenocarcinomas of the uterus, ovary, and cervix identified from 2016–2024. The report summarizes presentation, stage, treatments (all had upfront surgery; adjuvant therapy recommended), and short-term outcomes, finding that 9 of 13 had no evidence of disease at the time of writing and the cohort median overall survival was 15 months (95% CI: 2.2–27.8 months). The authors note that current literature suggests generally poor prognosis but their series includes several early-stage cases and relatively many patients without recurrence after initial treatment.

Reported effects: Total cases 13, n=13 · Anatomic distribution - uterine 6, n=13 · +12 more

Key findings

Total cases: 13 new MNAC/MLA cases identified at a single institution between 2016 and 2024.
Anatomic distribution: 6 uterine, 5 ovarian, and 2 cervical tumors.
Stage at presentation: 7 stage I, 2 stage II, 3 stage III, and 1 stage IV.
Treatment: All patients underwent upfront surgical resection; adjuvant therapy was recommended and one patient declined adjuvant treatment.
Outcomes at time of writing: 9 of 13 patients had completed treatment and had no evidence of disease, 1 was alive with disease, 1 was undergoing treatment, and 2 died of disease.
Median overall survival (OS) for the cohort was 15 months (95% CI: 2.2-27.8 months).

Limitations: Small sample size (n=13).; Single-institution, retrospective chart-review design.; Short and variable follow-up; outcomes are reported 'at the time of writing' and longer-term prognosis remains uncertain.; No control or comparison group; heterogeneous tumor anatomic sites and treatments limit generalizability.; Potential selection bias in case identification and reporting..

AI summary of the abstract, human-reviewed · Aug 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 48

Napsin-A Expression in Mesonephric and Mesonephric-like Adenocarcinomas: Implications for Distinction From Clear Cell Carcinoma

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · Nov 2025 · case series

mesonephric adenocarcinomamesonephric-like adenocarcinomaclear cell carcinomamesonephric carcinosarcoma

The authors performed Napsin-A immunohistochemistry on whole-slide sections from 48 mesonephric and mesonephric-like adenocarcinomas and carcinosarcomas. Napsin-A was positive in 17/48 cases (35.4%), with focal granular cytoplasmic staining in 1–40% of cells; positivity occurred in 13/32 MLAs, 2/13 MAs, and 2/3 carcinosarcomas. The study concludes that Napsin-A is expressed in a substantial subset of these tumors and that reliance on a single marker could lead to misclassification as clear cell carcinoma.

Reported effects: Napsin-A positive overall 35.4%, n=48 · Range of focal granular cytoplasmic expression · +3 more

Key findings

Napsin-A staining was positive in 17 of 48 cases (35.4%), with focal granular cytoplasmic expression ranging from 1% to 40%.
13/32 (40.6%) mesonephric-like adenocarcinomas (MLAs) were Napsin-A positive.
2/13 (15.4%) mesonephric adenocarcinomas (MAs) were Napsin-A positive.
2/3 (66.7%) mesonephric or mesonephric-like carcinosarcomas were Napsin-A positive.
Because of morphologic and immunohistochemical overlap, Napsin-A expression in MA/MLA may contribute to misclassification as clear cell carcinoma.

Limitations: Observational pathology series without reported clinical outcome correlation; Relatively small overall sample size and very small subgroup sizes (e.g., n=3 carcinosarcomas); Findings are based solely on immunohistochemistry on tissue sections; no clinical or molecular correlation reported in the abstract.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed